In Vivo and in Vitro Antiviral Effects of Berberine on Influenza Virus
Objective:To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.Methods:In vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells.In vivo anti-influenza virus assays were per...
Saved in:
Published in | Chinese journal of integrative medicine Vol. 17; no. 6; pp. 444 - 452 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Heidelberg
Chinese Association of Traditional and Western Medicine
01.06.2011
|
Subjects | |
Online Access | Get full text |
ISSN | 1672-0415 1993-0402 1993-0402 |
DOI | 10.1007/s11655-011-0640-3 |
Cover
Abstract | Objective:To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.Methods:In vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells.In vivo anti-influenza virus assays were performed on the viral pneumonia model of mice.The numbers of mice that died within day 2 to day 14 postinfection were recorded to calculate the mortality.On days 2,4,and 6,the viral titers in the lungs were determined by hemagglutination assay;hematoxylin/eosin staining was used to assess the pathogenic changes of lung tissues; the concentrations of tumor necrosis factor-alpha(TNF-α) and monocyte specific chemoattractant molecule (MCP-1) were measured by radio immunoassay or enzyme-linked immunosorbent assay;the concentrations of nitric oxide(NO) and inducible nitric oxide synthetase(iNOS) were detected by colorimetric method;reverse transcription polymerase chain reaction was used to detect the mRNA level of TNF-αand MCP-1.Results: Berberine showed inhibitory effects on cytopathogenic effects and neuraminidase activity of virus,with the therapeutic index 9.69.In vivo,berberine decreased mice mortality from 90%to 55%,reduced virus titers in the lungs on day 2 postinfection(P0.05).The lung histology scores were 1.50±0.67,4.50±1.00,and 5.50±1.00 in the berberine group on days 2,4,and 6,respectively,which were significantly reduced compared to 2.17±0.22,6.83±0.44,and 8.50±0.33 in the infected group(P0.05).The productions of NO and iNOS were repressed by berberine compared with those in the infected group(P0.01).The transcription and expression of TNF-αwere inhibited by berberine on day 4(P0.01) and day 6(P0.05),and those of MCP-1 were inhibited on day 6(P0.01) compared with the infected group.Conclusions:Berberine exhibited antiviral effects on the influenza virus both in vitro and in vivo.The possible therapeutic mechanism of berberine on influenza-induced viral pneumonia might be inhibiting the virus infection,as well as improving the pathogenic changes by repressing inflammatory substances release |
---|---|
AbstractList | Objective:To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.Methods:In vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells.In vivo anti-influenza virus assays were performed on the viral pneumonia model of mice.The numbers of mice that died within day 2 to day 14 postinfection were recorded to calculate the mortality.On days 2,4,and 6,the viral titers in the lungs were determined by hemagglutination assay;hematoxylin/eosin staining was used to assess the pathogenic changes of lung tissues; the concentrations of tumor necrosis factor-alpha(TNF-α) and monocyte specific chemoattractant molecule (MCP-1) were measured by radio immunoassay or enzyme-linked immunosorbent assay;the concentrations of nitric oxide(NO) and inducible nitric oxide synthetase(iNOS) were detected by colorimetric method;reverse transcription polymerase chain reaction was used to detect the mRNA level of TNF-αand MCP-1.Results: Berberine showed inhibitory effects on cytopathogenic effects and neuraminidase activity of virus,with the therapeutic index 9.69.In vivo,berberine decreased mice mortality from 90%to 55%,reduced virus titers in the lungs on day 2 postinfection(P0.05).The lung histology scores were 1.50±0.67,4.50±1.00,and 5.50±1.00 in the berberine group on days 2,4,and 6,respectively,which were significantly reduced compared to 2.17±0.22,6.83±0.44,and 8.50±0.33 in the infected group(P0.05).The productions of NO and iNOS were repressed by berberine compared with those in the infected group(P0.01).The transcription and expression of TNF-αwere inhibited by berberine on day 4(P0.01) and day 6(P0.05),and those of MCP-1 were inhibited on day 6(P0.01) compared with the infected group.Conclusions:Berberine exhibited antiviral effects on the influenza virus both in vitro and in vivo.The possible therapeutic mechanism of berberine on influenza-induced viral pneumonia might be inhibiting the virus infection,as well as improving the pathogenic changes by repressing inflammatory substances release Objective To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo . Methods In vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells. In vivo anti-influenza virus assays were performed on the viral pneumonia model of mice. The numbers of mice that died within day 2 to day 14 postinfection were recorded to calculate the mortality. On days 2, 4, and 6, the viral titers in the lungs were determined by hemagglutination assay; hematoxylin/eosin staining was used to assess the pathogenic changes of lung tissues; the concentrations of tumor necrosis factor-alpha (TNF-α) and monocyte specific chemoattractant molecule (MCP-1) were measured by radio immunoassay or enzyme-linked immunosorbent assay; the concentrations of nitric oxide (NO) and inducible nitric oxide synthetase (iNOS) were detected by colorimetric method; reverse transcription polymerase chain reaction was used to detect the mRNA level of TNF-α and MCP-1. Results Berberine showed inhibitory effects on cytopathogenic effects and neuraminidase activity of virus, with the therapeutic index 9.69. In vivo , berberine decreased mice mortality from 90% to 55%, reduced virus titers in the lungs on day 2 postinfection ( P <0.05). The lung histology scores were 1.50±0.67, 4.50±1.00, and 5.50±1.00 in the berberine group on days 2, 4, and 6, respectively, which were significantly reduced compared to 2.17±0.22, 6.83±0.44, and 8.50±0.33 in the infected group ( P <0.05). The productions of NO and iNOS were repressed by berberine compared with those in the infected group ( P <0.01). The transcription and expression of TNF-α were inhibited by berberine on day 4 ( P <0.01) and day 6 ( P <0.05), and those of MCP-1 were inhibited on day 6 ( P <0.01) compared with the infected group. Conclusions Berberine exhibited antiviral effects on the influenza virus both in vitro and in vivo . The possible therapeutic mechanism of berberine on influenza-induced viral pneumonia might be inhibiting the virus infection, as well as improving the pathogenic changes by repressing inflammatory substances release. To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.OBJECTIVETo explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.In vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells. In vivo anti-influenza virus assays were performed on the viral pneumonia model of mice. The numbers of mice that died within day 2 to day 14 postinfection were recorded to calculate the mortality. On days 2, 4, and 6, the viral titers in the lungs were determined by hemagglutination assay; hematoxylin/eosin staining was used to assess the pathogenic changes of lung tissues; the concentrations of tumor necrosis factor-alpha (TNF-α) and monocyte specific chemoattractant molecule (MCP-1) were measured by radio immunoassay or enzyme-linked immunosorbent assay; the concentrations of nitric oxide (NO) and inducible nitric oxide synthetase (iNOS) were detected by colorimetric method; reverse transcription polymerase chain reaction was used to detect the mRNA level of TNF-α and MCP-1.METHODSIn vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells. In vivo anti-influenza virus assays were performed on the viral pneumonia model of mice. The numbers of mice that died within day 2 to day 14 postinfection were recorded to calculate the mortality. On days 2, 4, and 6, the viral titers in the lungs were determined by hemagglutination assay; hematoxylin/eosin staining was used to assess the pathogenic changes of lung tissues; the concentrations of tumor necrosis factor-alpha (TNF-α) and monocyte specific chemoattractant molecule (MCP-1) were measured by radio immunoassay or enzyme-linked immunosorbent assay; the concentrations of nitric oxide (NO) and inducible nitric oxide synthetase (iNOS) were detected by colorimetric method; reverse transcription polymerase chain reaction was used to detect the mRNA level of TNF-α and MCP-1.Berberine showed inhibitory effects on cytopathogenic effects and neuraminidase activity of virus, with the therapeutic index 9.69. In vivo, berberine decreased mice mortality from 90% to 55%, reduced virus titers in the lungs on day 2 postinfection (P<0.05). The lung histology scores were 1.50 ± 0.67, 4.50 ± 1.00, and 5.50 ± 1.00 in the berberine group on days 2, 4, and 6, respectively, which were significantly reduced compared to 2.17 ± 0.22, 6.83 ± 0.44, and 8.50 ± 0.33 in the infected group (P<0.05). The productions of NO and iNOS were repressed by berberine compared with those in the infected group (P<0.01). The transcription and expression of TNF-α were inhibited by berberine on day 4 (P<0.01) and day 6 (P<0.05), and those of MCP-1 were inhibited on day 6 (P<0.01) compared with the infected group.RESULTSBerberine showed inhibitory effects on cytopathogenic effects and neuraminidase activity of virus, with the therapeutic index 9.69. In vivo, berberine decreased mice mortality from 90% to 55%, reduced virus titers in the lungs on day 2 postinfection (P<0.05). The lung histology scores were 1.50 ± 0.67, 4.50 ± 1.00, and 5.50 ± 1.00 in the berberine group on days 2, 4, and 6, respectively, which were significantly reduced compared to 2.17 ± 0.22, 6.83 ± 0.44, and 8.50 ± 0.33 in the infected group (P<0.05). The productions of NO and iNOS were repressed by berberine compared with those in the infected group (P<0.01). The transcription and expression of TNF-α were inhibited by berberine on day 4 (P<0.01) and day 6 (P<0.05), and those of MCP-1 were inhibited on day 6 (P<0.01) compared with the infected group.Berberine exhibited antiviral effects on the influenza virus both in vitro and in vivo. The possible therapeutic mechanism of berberine on influenza-induced viral pneumonia might be inhibiting the virus infection, as well as improving the pathogenic changes by repressing inflammatory substances release.CONCLUSIONSBerberine exhibited antiviral effects on the influenza virus both in vitro and in vivo. The possible therapeutic mechanism of berberine on influenza-induced viral pneumonia might be inhibiting the virus infection, as well as improving the pathogenic changes by repressing inflammatory substances release. To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo. In vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells. In vivo anti-influenza virus assays were performed on the viral pneumonia model of mice. The numbers of mice that died within day 2 to day 14 postinfection were recorded to calculate the mortality. On days 2, 4, and 6, the viral titers in the lungs were determined by hemagglutination assay; hematoxylin/eosin staining was used to assess the pathogenic changes of lung tissues; the concentrations of tumor necrosis factor-alpha (TNF-α) and monocyte specific chemoattractant molecule (MCP-1) were measured by radio immunoassay or enzyme-linked immunosorbent assay; the concentrations of nitric oxide (NO) and inducible nitric oxide synthetase (iNOS) were detected by colorimetric method; reverse transcription polymerase chain reaction was used to detect the mRNA level of TNF-α and MCP-1. Berberine showed inhibitory effects on cytopathogenic effects and neuraminidase activity of virus, with the therapeutic index 9.69. In vivo, berberine decreased mice mortality from 90% to 55%, reduced virus titers in the lungs on day 2 postinfection (P<0.05). The lung histology scores were 1.50 ± 0.67, 4.50 ± 1.00, and 5.50 ± 1.00 in the berberine group on days 2, 4, and 6, respectively, which were significantly reduced compared to 2.17 ± 0.22, 6.83 ± 0.44, and 8.50 ± 0.33 in the infected group (P<0.05). The productions of NO and iNOS were repressed by berberine compared with those in the infected group (P<0.01). The transcription and expression of TNF-α were inhibited by berberine on day 4 (P<0.01) and day 6 (P<0.05), and those of MCP-1 were inhibited on day 6 (P<0.01) compared with the infected group. Berberine exhibited antiviral effects on the influenza virus both in vitro and in vivo. The possible therapeutic mechanism of berberine on influenza-induced viral pneumonia might be inhibiting the virus infection, as well as improving the pathogenic changes by repressing inflammatory substances release. |
Author | 吴莹 李季倩 金叶智 吴珺 王谦 郝鈺 |
AuthorAffiliation | Key Laboratory of Chinese Medicine on Viral Diseases,Ministry of Education,Microbiology and Immunology Department,Beijing University of Chinese Medicine,Beijing(100029),China |
Author_xml | – sequence: 1 fullname: 吴莹 李季倩 金叶智 吴珺 王谦 郝鈺 |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21660679$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkDtPHDEURq0IFB7JD0gTmYpqgu94_NgSEJCVkGiA1vJ4r4nRrL3YMyD49Xi1G4oUKJWvrO_cxzkgOzFFJOQHsF_AmDopAFKIhgE0THas4V_IPsxmvGEda3dqLVVbaxB75KCUR8aEkkx8JXstSMmkmu2Ty3mk9-E5URsXNKzrMSd6GsfwHLId6IX36MZCk6dnmHvMISJNkc6jHyaMb7YSeSrfyK63Q8Hv2_eQ3F1e3J7_bq5vrubnp9eN66AdGxRSua5HK9gCuAONC4fYgVecM-u0xU5qbTlosICtwr7z9VsIFOB5j_yQtJu-U1zZ1xc7DGaVw9LmVwPMrKWYjRRTpZi1FMMrdLyBVjk9TVhGswzF4TDYiGkqRivgWs64rsmf2-TUL3Hx0fuvrxpQm4DLqZSM3rgw2jGkOGYbhk-XgH_I_1l8e22p2fiA2TymKccq-FPoaDvoT4oPT5X7mMQ1462qd74Dvcyn8w |
CitedBy_id | crossref_primary_10_3390_biom13010017 crossref_primary_10_3389_fmicb_2020_00621 crossref_primary_10_2147_DDDT_S299120 crossref_primary_10_1016_j_bmc_2014_09_004 crossref_primary_10_1080_01496395_2019_1666141 crossref_primary_10_1016_S1875_5364_16_30095_4 crossref_primary_10_1002_JLB_3MA0320_358RR crossref_primary_10_1142_S0192415X18500854 crossref_primary_10_1080_13880209_2023_2241518 crossref_primary_10_1002_med_21707 crossref_primary_10_1021_acsptsci_3c00292 crossref_primary_10_1080_07391102_2020_1778537 crossref_primary_10_1016_j_jep_2024_118258 crossref_primary_10_1016_j_intimp_2011_12_007 crossref_primary_10_1016_j_antiviral_2015_12_012 crossref_primary_10_1016_j_ijbiomac_2018_08_047 crossref_primary_10_3389_fphar_2023_1132388 crossref_primary_10_1002_ptr_6196 crossref_primary_10_14233_ajchem_2021_23365 crossref_primary_10_1080_07315724_2021_1958104 crossref_primary_10_3389_av_2023_11931 crossref_primary_10_1016_j_taap_2015_12_006 crossref_primary_10_3390_v4113179 crossref_primary_10_31857_S0033994624010019 crossref_primary_10_1038_s42004_023_00821_9 crossref_primary_10_3389_fimmu_2021_582556 crossref_primary_10_34172_jhp_2024_48132 crossref_primary_10_1007_s13659_022_00366_9 crossref_primary_10_1016_j_bmc_2021_116143 crossref_primary_10_1016_j_biopha_2019_109471 crossref_primary_10_1038_s41598_017_15733_7 crossref_primary_10_1016_j_jep_2024_118521 crossref_primary_10_1016_j_phrs_2020_105085 crossref_primary_10_2174_2211352521666230328123222 crossref_primary_10_1080_13880209_2019_1577466 crossref_primary_10_12677_CC_2018_24015 crossref_primary_10_3390_nu15224719 crossref_primary_10_1002_hsr2_641 crossref_primary_10_1016_j_antiviral_2021_105019 crossref_primary_10_1155_2022_7137401 crossref_primary_10_1002_ptr_5693 crossref_primary_10_1007_s11101_023_09855_2 crossref_primary_10_1186_s12985_025_02666_1 crossref_primary_10_3390_v11010049 crossref_primary_10_1186_s13568_020_01088_2 crossref_primary_10_3390_ijms26051823 crossref_primary_10_1186_s12906_016_1206_x crossref_primary_10_1016_j_bmc_2017_07_006 crossref_primary_10_1007_s11356_021_16280_5 crossref_primary_10_1002_jmv_26747 crossref_primary_10_1016_j_jchromb_2025_124507 crossref_primary_10_3390_v12030344 crossref_primary_10_1016_j_biopha_2021_111676 crossref_primary_10_1016_j_biopha_2022_113523 crossref_primary_10_3184_175815516X14725499175700 crossref_primary_10_3389_fimmu_2023_1257988 crossref_primary_10_1002_ptr_6770 crossref_primary_10_17221_6746_VETMED crossref_primary_10_1186_s13020_019_0277_2 crossref_primary_10_1016_j_phymed_2013_04_009 crossref_primary_10_3390_d12050175 crossref_primary_10_38059_biodiversity_1306614 crossref_primary_10_1016_j_jprot_2020_103666 crossref_primary_10_1016_j_prmcm_2024_100362 |
Cites_doi | 10.1128/AAC.40.11.2626 10.1016/S0047-6374(00)00204-9 10.1093/toxsci/kfn131 10.1086/516358 10.1111/j.1749-6632.1965.tb12533.x 10.1016/0006-291X(90)92357-6 10.1248/bpb.18.295 10.1182/blood.V88.8.3230.bloodjournal8883230 10.4049/jimmunol.182.3.1296 10.1128/JVI.02602-07 10.3949/ccjm.67.2.92 10.1111/j.1745-7254.2008.00786.x 10.1016/1357-4310(96)88772-7 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L 10.4049/jimmunol.180.4.2562 10.1002/14651858.CD001169.pub2 10.1142/S0192415X99000082 10.1073/pnas.93.6.2448 |
ContentType | Journal Article |
Copyright | Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2011 |
Copyright_xml | – notice: Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2011 |
DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
DOI | 10.1007/s11655-011-0640-3 |
DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | In Vivo and in Vitro Antiviral Effects of Berberine on Influenza Virus |
EISSN | 1993-0402 |
EndPage | 452 |
ExternalDocumentID | 10.1007/s11655-011-0640-3 21660679 10_1007_s11655_011_0640_3 38032738 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 29B 29~ 2B. 2C~ 2J2 2JN 2JY 2KG 2KM 2LR 2RA 2VQ 2~H 30V 36B 4.4 406 408 40D 40E 5GY 5VR 5VS 6NX 6PF 92F 92I 92L 93N 93R 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYQN AAYTO ABDZT ABECU ABFGW ABFTV ABHQN ABJNI ABJOX ABKAS ABKCH ABMNI ABMQK ABNWP ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACBMV ACBRV ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACSNA ACTTH ACUDM ACVWB ACWMK ACZOJ ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFLOW AFNRJ AFQWF AFUIB AFWTZ AFZKB AGAYW AGDGC AGGBP AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BGNMA CAG CCEZO CHBEP CIEJG COF CQIGP CS3 CSCUP CW9 DDRTE DNIVK DPUIP DU5 EBLON EBS EIOEI EJD EMB EMOBN ESBYG F5P FA0 FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI HF~ HG6 HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ ITM IWAJR I~X I~Z J-C JBSCW JZLTJ LLZTM M4Y MA- NDZJH NPVJJ NQJWS NU0 O9- P9S PF0 PT4 QOR QOS R89 R9I ROL RPX RSV S16 S1Z S26 S27 S28 S37 S3B SAP SCL SCLPG SDH SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE SV3 SZ9 SZN T13 T16 TCJ TGQ TSG TT1 TUC U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 W91 WFFXF WK8 YLTOR Z7U ZMTXR ZOVNA ~A9 ~WA -SE -S~ AACDK AAJBT AAPKM AASML AAYZH ABAKF ABBRH ABDBE ABQSL ACDTI ACPIV ADHKG AEFQL AEMSY AFBBN AFDZB AGQEE AGQPQ AGRTI AHPBZ AIGIU AYFIA CAJEE H13 Q-- SJYHP U1G U5O AAYXX ABFSG ABRTQ ACSTC AEZWR AFHIU AFOHR AHWEU AIXLP ATHPR CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
ID | FETCH-LOGICAL-c412t-e567c4bea50d13c18edcee41f7330ac8ae4688a3181a1e27eb4fac855e51f3be3 |
IEDL.DBID | AGYKE |
ISSN | 1672-0415 1993-0402 |
IngestDate | Tue Aug 19 21:38:43 EDT 2025 Fri Sep 05 00:01:04 EDT 2025 Fri Apr 11 01:31:20 EDT 2025 Wed Oct 01 06:34:15 EDT 2025 Thu Apr 24 23:09:08 EDT 2025 Thu Apr 10 07:58:22 EDT 2025 Wed Feb 14 09:54:40 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | influenza virus antiviral effects berberine |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c412t-e567c4bea50d13c18edcee41f7330ac8ae4688a3181a1e27eb4fac855e51f3be3 |
Notes | 11-4928/R in vivo ;in vitro ;antiviral effects ;berberine ;influenza virus Objective:To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.Methods:In vitro anti-influenza virus assays were performed by cytopathogenic effect and neuraminidase assays in Madin Darby canine kidney cells.In vivo anti-influenza virus assays were performed on the viral pneumonia model of mice.The numbers of mice that died within day 2 to day 14 postinfection were recorded to calculate the mortality.On days 2,4,and 6,the viral titers in the lungs were determined by hemagglutination assay;hematoxylin/eosin staining was used to assess the pathogenic changes of lung tissues; the concentrations of tumor necrosis factor-alpha(TNF-α) and monocyte specific chemoattractant molecule (MCP-1) were measured by radio immunoassay or enzyme-linked immunosorbent assay;the concentrations of nitric oxide(NO) and inducible nitric oxide synthetase(iNOS) were detected by colorimetric method;reverse transcription polymerase chain reaction was used to detect the mRNA level of TNF-αand MCP-1.Results: Berberine showed inhibitory effects on cytopathogenic effects and neuraminidase activity of virus,with the therapeutic index 9.69.In vivo,berberine decreased mice mortality from 90%to 55%,reduced virus titers in the lungs on day 2 postinfection(P0.05).The lung histology scores were 1.50±0.67,4.50±1.00,and 5.50±1.00 in the berberine group on days 2,4,and 6,respectively,which were significantly reduced compared to 2.17±0.22,6.83±0.44,and 8.50±0.33 in the infected group(P0.05).The productions of NO and iNOS were repressed by berberine compared with those in the infected group(P0.01).The transcription and expression of TNF-αwere inhibited by berberine on day 4(P0.01) and day 6(P0.05),and those of MCP-1 were inhibited on day 6(P0.01) compared with the infected group.Conclusions:Berberine exhibited antiviral effects on the influenza virus both in vitro and in vivo.The possible therapeutic mechanism of berberine on influenza-induced viral pneumonia might be inhibiting the virus infection,as well as improving the pathogenic changes by repressing inflammatory substances release WU Ying ,LI Ji-qian,KIM Ye-ji, WU Jun, WANG Qian, HAO Yu (Key Laboratory of Chinese Medicine on Viral Diseases,Ministry of Education,Microbiology and Immunology Department,Beijing University of Chinese Medicine,Beijing(100029),China ) ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://link.springer.com/content/pdf/10.1007/s11655-011-0640-3.pdf |
PMID | 21660679 |
PQID | 871386938 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | unpaywall_primary_10_1007_s11655_011_0640_3 proquest_miscellaneous_871386938 pubmed_primary_21660679 crossref_citationtrail_10_1007_s11655_011_0640_3 crossref_primary_10_1007_s11655_011_0640_3 springer_journals_10_1007_s11655_011_0640_3 chongqing_primary_38032738 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2011-06-01 |
PublicationDateYYYYMMDD | 2011-06-01 |
PublicationDate_xml | – month: 06 year: 2011 text: 2011-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Heidelberg |
PublicationPlace_xml | – name: Heidelberg – name: China |
PublicationTitle | Chinese journal of integrative medicine |
PublicationTitleAbbrev | Chin. J. Integr. Med |
PublicationTitleAlternate | Chinese Journal of Integrative Medicine |
PublicationYear | 2011 |
Publisher | Chinese Association of Traditional and Western Medicine |
Publisher_xml | – name: Chinese Association of Traditional and Western Medicine |
References | L.J. Reed (640_CR12) 1938; 27 640_CR4 J.B. Wu (640_CR10) 2009; 34 T. Hussell (640_CR19) 2001; 31 H.M. Kim (640_CR1) 2008; 82 J.K. Long (640_CR5) 2000; 67 J. Wang (640_CR17) 2009; 182 J. Ehrlich (640_CR11) 1965; 130 R.W. Sidwell (640_CR15) 1996; 40 T. Akaike (640_CR22) 1996; 93 C.V. Pereira (640_CR16) 2008; 105 K.R. Cooke (640_CR14) 1996; 88 D.J. Stuehr (640_CR21) 1990; 168 K.L. Lin (640_CR23) 2008; 180 Y.J. Guo (640_CR13) 1997 J.A. Englund (640_CR3) 1998; 26 Y. Luo (640_CR8) 2008; 29 B.J. Rollins (640_CR18) 1996; 2 Q. Ouyang (640_CR2) 2000; 121 T. Nagai (640_CR6) 1995; 18 J.B. Wu (640_CR9) 2007; 40 640_CR20 M. Kobayashi (640_CR7) 1999; 27 |
References_xml | – volume: 34 start-page: 376 year: 2009 ident: 640_CR10 publication-title: Chin J Antibiot (Chin) – volume: 40 start-page: 2626 year: 1996 ident: 640_CR15 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.40.11.2626 – volume: 121 start-page: 131 year: 2000 ident: 640_CR2 publication-title: Mech Ageing Dev doi: 10.1016/S0047-6374(00)00204-9 – volume: 105 start-page: 408 year: 2008 ident: 640_CR16 publication-title: Toxicol Sci doi: 10.1093/toxsci/kfn131 – volume: 26 start-page: 1418 year: 1998 ident: 640_CR3 publication-title: Clin Infect Dis doi: 10.1086/516358 – volume: 130 start-page: 5 year: 1965 ident: 640_CR11 publication-title: Ann NY Acad Sci doi: 10.1111/j.1749-6632.1965.tb12533.x – ident: 640_CR20 – volume: 168 start-page: 558 year: 1990 ident: 640_CR21 publication-title: Biochem Biophys Res Commun doi: 10.1016/0006-291X(90)92357-6 – volume: 18 start-page: 295 year: 1995 ident: 640_CR6 publication-title: Biol Pharm Bull doi: 10.1248/bpb.18.295 – volume: 88 start-page: 3230 year: 1996 ident: 640_CR14 publication-title: Blood doi: 10.1182/blood.V88.8.3230.bloodjournal8883230 – volume: 27 start-page: 493 year: 1938 ident: 640_CR12 publication-title: Am J Hyg – volume: 182 start-page: 1296 year: 2009 ident: 640_CR17 publication-title: J Immunol doi: 10.4049/jimmunol.182.3.1296 – volume: 82 start-page: 4265 year: 2008 ident: 640_CR1 publication-title: J Virol doi: 10.1128/JVI.02602-07 – volume: 67 start-page: 92 year: 2000 ident: 640_CR5 publication-title: Cleve Clin J Med doi: 10.3949/ccjm.67.2.92 – volume: 29 start-page: 628 year: 2008 ident: 640_CR8 publication-title: Acta Pharmacol Sin doi: 10.1111/j.1745-7254.2008.00786.x – volume: 40 start-page: 671 year: 2007 ident: 640_CR9 publication-title: Chin J Dermatol (Chin) – volume: 2 start-page: 198 year: 1996 ident: 640_CR18 publication-title: Mol Med Today doi: 10.1016/1357-4310(96)88772-7 – volume: 31 start-page: 2566 year: 2001 ident: 640_CR19 publication-title: Eur J Immunol doi: 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L – start-page: 111 volume-title: Influenza virus and experimental technique year: 1997 ident: 640_CR13 – volume: 180 start-page: 2562 year: 2008 ident: 640_CR23 publication-title: J Immunol doi: 10.4049/jimmunol.180.4.2562 – ident: 640_CR4 doi: 10.1002/14651858.CD001169.pub2 – volume: 27 start-page: 53 year: 1999 ident: 640_CR7 publication-title: Am J Chin Med doi: 10.1142/S0192415X99000082 – volume: 93 start-page: 2448 year: 1996 ident: 640_CR22 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.6.2448 |
SSID | ssj0057605 |
Score | 2.1630824 |
Snippet | Objective:To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.Methods:In vitro anti-influenza virus assays... Objective To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo . Methods In vitro anti-influenza virus assays... To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo. In vitro anti-influenza virus assays were performed by... To explore the potential effects of berberine on influenza virus infection both in vitro and in vivo.OBJECTIVETo explore the potential effects of berberine on... |
SourceID | unpaywall proquest pubmed crossref springer chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 444 |
SubjectTerms | Animals Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Berberine - pharmacology Berberine - therapeutic use Cell Line Chemokine CCL2 - genetics Chemokine CCL2 - metabolism Dogs Female Lung - drug effects Lung - enzymology Lung - pathology Lung - virology Male Medicine Medicine & Public Health Mice Neuraminidase - metabolism Nitric Oxide - metabolism Nitric Oxide Synthase Type II - metabolism Original Article Orthomyxoviridae - drug effects Orthomyxoviridae - enzymology Orthomyxoviridae Infections - complications Orthomyxoviridae Infections - drug therapy Orthomyxoviridae Infections - pathology Orthomyxoviridae Infections - virology Pneumonia - complications Pneumonia - drug therapy Pneumonia - pathology Pneumonia - virology Reactive Oxygen Species - metabolism Survival Analysis Transcription, Genetic - drug effects Tumor Necrosis Factor-alpha - genetics Tumor Necrosis Factor-alpha - metabolism |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3ZTtwwcEQXqepL7yO0ID_0qSjLOnauR4S6AiRQH7oSfbJsx2kRK2e7m4Dg6zuTY6GtSlX1LYfH14zHY88F8N6SN6bJeGhSXoayzBzyQSlDZ1GaEEUuCk3eyCenyeFMHp_FZxtwMPjCtNbug0qy82mgKE2-3lsU5d6t4xtPYjI6I6sdiYxkjH8fwGZCWqYRbM5OP-1_oaNWkkYhOaG3umWyVGvteYI_1kMRFr5V_ut3bP_nneo38fOO6hShGr_Q11d6Pr-zO02fQDGMqzNKuRg3tRnbm19CPv7nwJ_C4156ZfsduT2DDeefw8OTXj__AqZHnl2eX1ZM-4Kd03O9pBdKUbFEwN56hFUlM4jP1vWQVR6LtqlSbjRCLJvVS5hNP34-OAz7TA2hlTyqQxcnqZXG6XhScGF5RralTvIyFWKibaadTLJMI__gmrsodUaW-DmOXcxLYZx4BSNfefcGGG6lsTWRo5iSssilSV2qXYkHKZTkeG4D2FpjSC26iBxKZBNBPkYBTAaUKdvHOKdUG3N1G52ZJlDhBCqaQCUC-LAGGaq7pzAb6EDhMiTdivaualYKz50iS3LqwuuOPta1RRzJMknzAHYH_KqeUazua2p3TVN_79jWP5V-C4-6q3G6THoHo3rZuG2UrWqz06-dHzSxFsE priority: 102 providerName: Unpaywall |
Title | In Vivo and in Vitro Antiviral Effects of Berberine on Influenza Virus |
URI | http://lib.cqvip.com/qk/86437A/201106/38032738.html https://link.springer.com/article/10.1007/s11655-011-0640-3 https://www.ncbi.nlm.nih.gov/pubmed/21660679 https://www.proquest.com/docview/871386938 https://link.springer.com/content/pdf/10.1007/s11655-011-0640-3.pdf |
UnpaywallVersion | publishedVersion |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1993-0402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057605 issn: 1672-0415 databaseCode: AFBBN dateStart: 19970301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1993-0402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057605 issn: 1672-0415 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1993-0402 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057605 issn: 1672-0415 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbtQwcES3EuJS3nQLVD5wokq1ju0ke1yhLgXUikNXak-W7ThQsXLKblJEv56ZTbwtDxX1Fkee8WPs8djzAnjjyBvTFjyxOa8SWRUe-aCUiXcoTYhyLEpD3shHx9nhTH48Vae9H_cyWrtHleSKU187u_FMkaEZWepIZB4bsKnofjKAzcn7s08HkQGjBL2yXORZnibkgR6Vmf9CQiEVvtbhy3ds8Pej6S9584auFKHacGF-_jDz-Y3jaPoQTuJAOiuUb_ttY_fd1R8xHu840kew1YunbNKtp8dwz4cncP-oV8A_hemHwC7PL2tmQsnO6btZUIFyUCwQsDcPYXXFLBJs5VvI6oBVV7lQrgxCLNrlM5hND07eHSZ9KobESZ42iVdZ7qT1Ro1KLhwvyHjUS17lQoyMK4yXWVEYZBDccJ_m3soKfyvlFa-E9eI5DEId_DYwPCuVs6mnoJGyHEub-9z4Cm9KKKrxsRvCzpoi-qILuaFFMRLkRDSEUSSRdn0Qc8qlMdfX4Zdp8jROnqbJ02IIb9cgEd0tlVmku8Z9RsoTE3zdLjVeLEWRjakLL7r1sMaW8iyj97gh7EV66p4TLG9ram-9hv7fsZ074X4JD7q3b3otegWDZtH61yg8NXa33yy7sDFLJ1iaHX-enP0CkJkN9Q |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1db9Mw8ASdBLwwvtcxIA88MWWqYydxHye0rmPrnjppPFm248BE5WxtMsR-PXdN3A2GhvYWR77zx9nns-8L4KMlb0wjWWxyVsailA75oBCxsyhN8GLIC03eyJPjbHwivpymp50f9yJYuweV5JJTXzu7sSwlQzOy1BHIPB7CmmBSih6s7e5_PdwLDBgl6KXlIsvyJCYP9KDM_BcSCqnwvfLfLrDBP4-mW_LmDV0pQjX-XP_6qWezG8fRaB2mYSCtFcqPnaY2O_bqrxiP9xzpM3jaiafRbruensMD51_Ao0mngH8JowMfXZ5dVpH2RXRG3_WcCpSDYo6AnXlIVJWRQYItfQujymPVZS6UK40Q82bxCk5Ge9PP47hLxRBbwZI6dmmWW2GcTgcF45ZJMh51gpU55wNtpXYik1Ijg2CauSR3RpT4O01dykpuHH8NPV95twERnpWpNYmjoJGiGAqTu1y7Em9KKKqxoe3D5ooi6rwNuaG4HHByIurDIJBI2S6IOeXSmKnr8Ms0eQonT9HkKd6HTyuQgO6OylGgu8J9RsoT7V3VLBReLLnMhtSFN-16WGFLWJbRe1wftgM9VccJFnc1tb1aQ__v2Oa9cH-Ax-Pp5EgdHRwfvoUn7Ts4vRxtQa-eN-4dClK1ed9tnN-hFw5N |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LTtwwcERBQr1ULfSxtAUfeiqKWMfOY4-osOJREAdW4mbZzqRFWjnb3SxV-_Wd2SQLCATqLY48Y2vG9ow9L4AvnqMxXS4jl8ky0mWOdA5qHaEnbUIVA1VYjkY-O0-PRvrkKrlq65zOOm_3ziTZxDRwlqZQ702Kcu828E2mCTudsdeOpoPkBaxpEtV8-xrF-91RTLr0wodRplkccSx6Z9Z8DAUnV_hZhR-_aOj7QuqB5nnHakpQ8zCxf37b8fiOYBq-hletRin2myXwBlYwbMD6WWsz34ThcRA31zeVsKEQ1_xdT7nBZSOmBNh6dIiqFI5ovAgHFFWgrovyJX8tQUzns7cwGh5efjuK2uoJkSdS1BEmaea1Q5v0C6m8zNnfE7UsM6X61ucWdZrnlva0tBLjDJ0u6XeSYCJL5VC9g9VQBfwAgsRb4l2MnOdRFwPtMswslnS5Ie1KDnwPtpakM5MmS4ZReV9x3E8P-h0tjW_zjnP5i7G5zZjMrDDECsOsMKoHX5cgHbonOouOQYa2Bts7bMBqPjN0F1R5OuApvG8Yt8QWyzTlJ7Qe7HacNO3mnT011O6S2c9PbOu_cO_A-sXB0Hw_Pj_9CC-bl2t-6_kEq_V0jp9J9and9mJ5_wO7HPXC |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3ZTtwwcEQXqepL7yO0ID_0qSjLOnauR4S6AiRQH7oSfbJsx2kRK2e7m4Dg6zuTY6GtSlX1LYfH14zHY88F8N6SN6bJeGhSXoayzBzyQSlDZ1GaEEUuCk3eyCenyeFMHp_FZxtwMPjCtNbug0qy82mgKE2-3lsU5d6t4xtPYjI6I6sdiYxkjH8fwGZCWqYRbM5OP-1_oaNWkkYhOaG3umWyVGvteYI_1kMRFr5V_ut3bP_nneo38fOO6hShGr_Q11d6Pr-zO02fQDGMqzNKuRg3tRnbm19CPv7nwJ_C4156ZfsduT2DDeefw8OTXj__AqZHnl2eX1ZM-4Kd03O9pBdKUbFEwN56hFUlM4jP1vWQVR6LtqlSbjRCLJvVS5hNP34-OAz7TA2hlTyqQxcnqZXG6XhScGF5RralTvIyFWKibaadTLJMI__gmrsodUaW-DmOXcxLYZx4BSNfefcGGG6lsTWRo5iSssilSV2qXYkHKZTkeG4D2FpjSC26iBxKZBNBPkYBTAaUKdvHOKdUG3N1G52ZJlDhBCqaQCUC-LAGGaq7pzAb6EDhMiTdivaualYKz50iS3LqwuuOPta1RRzJMknzAHYH_KqeUazua2p3TVN_79jWP5V-C4-6q3G6THoHo3rZuG2UrWqz06-dHzSxFsE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vivo+and+in+vitro+antiviral+effects+of+berberine+on+influenza+virus&rft.jtitle=Chinese+journal+of+integrative+medicine&rft.au=Wu%2C+Ying&rft.au=Li%2C+Ji-qian&rft.au=Kim%2C+Ye-ji&rft.au=Wu%2C+Jun&rft.date=2011-06-01&rft.issn=1672-0415&rft.eissn=1993-0402&rft.volume=17&rft.issue=6&rft.spage=444&rft.epage=452&rft_id=info:doi/10.1007%2Fs11655-011-0640-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s11655_011_0640_3 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F86437A%2F86437A.jpg |